US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
META
$728.08
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
NVDA
$233.95
▲+0.00%
JNJ
$256.03
▲+0.00%
SPCX
$158.96
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
META
$728.08
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
NVDA
$233.95
▲+0.00%
JNJ
$256.03
▲+0.00%
SPCX
$158.96
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by TScan Therapeutics, Inc.
< Previous
1
2
3
Next >
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
September 02, 2026
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
July 29, 2026
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 24, 2026
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
June 22, 2026
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 06, 2026
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
April 27, 2026
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 04, 2026
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
February 26, 2026
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
February 25, 2026
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
December 06, 2025
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
December 03, 2025
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 12, 2025
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
November 05, 2025
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
November 03, 2025
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
September 17, 2025
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics to Participate in Upcoming Investor Conferences
September 03, 2025
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 12, 2025
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
May 28, 2025
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 06, 2025
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting
April 28, 2025
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
March 31, 2025
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access
March 27, 2025
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 05, 2025
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference
February 27, 2025
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
February 18, 2025
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
December 26, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
December 23, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FCNCA
TCRX
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
December 09, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
December 05, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
< Previous
1
2
3
Next >
